Korhan Soylu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Korhan Soylu has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Okan Gulel
Department of Cardiology, Faculty of Medicine, Ondokuz Mayıs University; Samsun-Turkey
8 shared publications- Serkan Yuksel
Department of Cardiology, Faculty of Medicine, Ondokuz Mayis University, Samsun 55139, Türkiye
7 shared publications Gökhan Aksan
Department of Cardiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
5 shared publicationsSerkan Yuksel
Cardiology Department, Faculty of Medicine, Ondokuz Mayis University, Turkey
5 shared publications- Ufuk Yildirim
Ondokuz Mayis University Samsun Turkey
5 shared publications Ömer Gedikli
Cardiology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
5 shared publications
Latest Publications
- 14 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 601-609
Impact of Isolated Side Branch Lesions on Procedural Techniques and Outcomes of Bifurcation Percutaneous Coronary Intervention
Background: There is limited information on the impact of the isolated side branch lesions (ISBL) on the procedural techniques and outcomes of bifurcation percutaneous coronary intervention (PCI). Aims: To examine the clinical, procedural and long‐term outcomes of ISBL. Methods: We examined the clinical, angiographic characteristics, and procedural outcomes of 1719 bifurcation PCIs in 1501 patients between 2014 and 2023 from the PROGRESS‐BIFURCATION registry. A propensity score matched (PSM) Cox proportional hazards model was used to assess long‐term outcomes. Results: ISBL (Medina class 0,0,1) was present in 80 patients (5.3%). ISBL patients had similar baseline characteristics to the remaining patients, except for hypertension (90.0% vs. 79.2%, p = 0.020), prior PCI (66.3% vs. 44.5%, p < 0.001), and prior MI (50.6% vs. 35.2%, p = 0.006) that were more common in ISBL patients. ISBL had a median side branch diameter of 2.5 mm (interquartile range [IQR] 2.5−3.0), a median length of 10 mm (IQR 5−12), and a median side branch stenosis of 90% (IQR 80−95). The most common stenting strategies were side branch stenting (41.8%) and inverted provisional (25.5%). Technical and procedural success and in‐hospital major adverse cardiovascular events (MACE) were similar in patients with and without ISBL. At 3‐year follow‐up, the incidence of MACE was higher in ISBL patients (36.3% vs. 26.4%, p = 0.043), driven by higher repeat target vessel PCI (26.8% vs. 12.0%; p = 0.003). On PSM adjusted Cox analysis, ISBL were independently associated with higher follow‐up MACE (hazard ratio 1.58, 95% confidence intervals 1.13−2.20, p = 0.008). Conclusions: PCI of ISBL was infrequent and was associated with similar technical and procedural success with non‐ISBL but higher long‐term MACE driven by higher TVR.
- 14 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 601-609
Impact of Isolated Side Branch Lesions on Procedural Techniques and Outcomes of Bifurcation Percutaneous Coronary Intervention
Background: There is limited information on the impact of the isolated side branch lesions (ISBL) on the procedural techniques and outcomes of bifurcation percutaneous coronary intervention (PCI). Aims: To examine the clinical, procedural and long‐term outcomes of ISBL. Methods: We examined the clinical, angiographic characteristics, and procedural outcomes of 1719 bifurcation PCIs in 1501 patients between 2014 and 2023 from the PROGRESS‐BIFURCATION registry. A propensity score matched (PSM) Cox proportional hazards model was used to assess long‐term outcomes. Results: ISBL (Medina class 0,0,1) was present in 80 patients (5.3%). ISBL patients had similar baseline characteristics to the remaining patients, except for hypertension (90.0% vs. 79.2%, p = 0.020), prior PCI (66.3% vs. 44.5%, p < 0.001), and prior MI (50.6% vs. 35.2%, p = 0.006) that were more common in ISBL patients. ISBL had a median side branch diameter of 2.5 mm (interquartile range [IQR] 2.5−3.0), a median length of 10 mm (IQR 5−12), and a median side branch stenosis of 90% (IQR 80−95). The most common stenting strategies were side branch stenting (41.8%) and inverted provisional (25.5%). Technical and procedural success and in‐hospital major adverse cardiovascular events (MACE) were similar in patients with and without ISBL. At 3‐year follow‐up, the incidence of MACE was higher in ISBL patients (36.3% vs. 26.4%, p = 0.043), driven by higher repeat target vessel PCI (26.8% vs. 12.0%; p = 0.003). On PSM adjusted Cox analysis, ISBL were independently associated with higher follow‐up MACE (hazard ratio 1.58, 95% confidence intervals 1.13−2.20, p = 0.008). Conclusions: PCI of ISBL was infrequent and was associated with similar technical and procedural success with non‐ISBL but higher long‐term MACE driven by higher TVR.
- 24 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (6) , 1349-1355
Impact of Side Branch Predilatation on Provisional Bifurcation Percutaneous Coronary Intervention Outcomes: Insights From PROGRESS‐BIFURCATION Registry
Background: Whether side branch (SB) predilatation should be performed in patients undergoing bifurcation percutaneous coronary interventions (PCI) remains controversial.Methods: We performed an observational cohort study across six international centers from 2013 to 2024, as part of the Prospective Global Registry of PCI in Bifurcation Lesions (PROGRESS‐BIFURCATION). We analyzed procedural characteristics and in‐hospital outcomes of patients undergoing provisional bifurcation PCI with and without SB lesion predilatation. Significant SB lesions were defined as those with ≥50% diameter stenosis. Multivariable adjusted hazard ratios (aHR) with 95% confidence intervals [CI] were calculated using mixed effects Cox regression.Results: Of 1042 lesions treated with provisional bifurcation PCI, 428 (41.1%) had significant SB lesions (true bifurcation lesions). Among these, 143 (33.4%) underwent predilatation. Lesions that underwent SB predilatation had longer SB lesion length (median 10.0 mm [IQR 5.0−10.0] vs. 5.0 mm [IQR 5.0−10.0], p = 0.001) and more SB diameter stenosis (median 90% [IQR 70%−95%] vs. 70% [IQR 60−90]). Technical success (95.1% vs. 87.7%; p = 0.015) and procedural success (93.7% vs. 82.8%; p = 0.003) were more common in the SB predilatation group, although the rates of crossover to a 2‐stent technique were also higher in the SB predilatation group (23.1% vs. 10.9%; p < 0.001). The incidence of procedural complications (22.3% vs. 21.3%, p = 0.897) and in‐hospital major adverse cardiovascular events (2.4% vs. 6.4%, p = 0.097) was similar between the groups.Conclusion: In provisional bifurcation PCI of true bifurcation lesions, SB predilatation was performed in approximately one‐third and was associated with higher technical and procedural success, higher rates to crossover to a 2‐stent technique, and similar incidence of in‐hospital and long‐term follow‐up outcomes.
- 24 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (6) , 1349-1355
Impact of Side Branch Predilatation on Provisional Bifurcation Percutaneous Coronary Intervention Outcomes: Insights From PROGRESS‐BIFURCATION Registry
Background: Whether side branch (SB) predilatation should be performed in patients undergoing bifurcation percutaneous coronary interventions (PCI) remains controversial.Methods: We performed an observational cohort study across six international centers from 2013 to 2024, as part of the Prospective Global Registry of PCI in Bifurcation Lesions (PROGRESS‐BIFURCATION). We analyzed procedural characteristics and in‐hospital outcomes of patients undergoing provisional bifurcation PCI with and without SB lesion predilatation. Significant SB lesions were defined as those with ≥50% diameter stenosis. Multivariable adjusted hazard ratios (aHR) with 95% confidence intervals [CI] were calculated using mixed effects Cox regression.Results: Of 1042 lesions treated with provisional bifurcation PCI, 428 (41.1%) had significant SB lesions (true bifurcation lesions). Among these, 143 (33.4%) underwent predilatation. Lesions that underwent SB predilatation had longer SB lesion length (median 10.0 mm [IQR 5.0−10.0] vs. 5.0 mm [IQR 5.0−10.0], p = 0.001) and more SB diameter stenosis (median 90% [IQR 70%−95%] vs. 70% [IQR 60−90]). Technical success (95.1% vs. 87.7%; p = 0.015) and procedural success (93.7% vs. 82.8%; p = 0.003) were more common in the SB predilatation group, although the rates of crossover to a 2‐stent technique were also higher in the SB predilatation group (23.1% vs. 10.9%; p < 0.001). The incidence of procedural complications (22.3% vs. 21.3%, p = 0.897) and in‐hospital major adverse cardiovascular events (2.4% vs. 6.4%, p = 0.097) was similar between the groups.Conclusion: In provisional bifurcation PCI of true bifurcation lesions, SB predilatation was performed in approximately one‐third and was associated with higher technical and procedural success, higher rates to crossover to a 2‐stent technique, and similar incidence of in‐hospital and long‐term follow‐up outcomes.
- Open Access
Optimising Percutaneous Coronary Interventions: The Impact of Stent Type and Diameter on Long-Term Clinical Outcomes in Large Coronary Arteries
Background and Objectives: Our study aimed to reveal the effect of using 4 mm bare-metal stents (BMS), 4 mm drug-eluting stents (DES), or 3 mm DES with 4 mm diameter balloon post-dilation strategies on long-term clinical outcomes and endpoints for large-diameter coronary artery percutaneous coronary intervention (PCI). Materials and Methods: In our study, patients who had undergone PCI were retrospectively screened between January 2014 and July 2020. The study included 350 patients and was divided into three groups; Group I (n = 134) included patients with direct 4.0 mm BMS implantation, Group II (n = 109) included patients with direct 4.0 DES implantation, and Group III (n = 107) included patients with 4mm NC post-dilatation after 3 mm DES implantation. Primary endpoints were determined as target lesion revascularisation, cardiac mortality, and myocardial infarction associated with the target vessel. Our secondary endpoint was all-cause mortality. Results: No differences were observed between the groups in terms of the baseline variables. Stent length was the highest in Group II and the shortest in Group III. There were no significant differences between the groups regarding major adverse cardiovascular events (MACE). Conclusions: Our study suggests that in percutaneous coronary interventions for non-complex lesions, there is no significant difference in MACE outcomes when directly implanting a 4 mm diameter DES, a 4 mm diameter BMS, or a 3 mm diameter DES, followed by post-dilation with an appropriately sized NC balloon when the target vessel diameter is in the range of 4 to 4.4 mm.
Open AccessOptimising Percutaneous Coronary Interventions: The Impact of Stent Type and Diameter on Long-Term Clinical Outcomes in Large Coronary Arteries
Background and Objectives: Our study aimed to reveal the effect of using 4 mm bare-metal stents (BMS), 4 mm drug-eluting stents (DES), or 3 mm DES with 4 mm diameter balloon post-dilation strategies on long-term clinical outcomes and endpoints for large-diameter coronary artery percutaneous coronary intervention (PCI). Materials and Methods: In our study, patients who had undergone PCI were retrospectively screened between January 2014 and July 2020. The study included 350 patients and was divided into three groups; Group I (n = 134) included patients with direct 4.0 mm BMS implantation, Group II (n = 109) included patients with direct 4.0 DES implantation, and Group III (n = 107) included patients with 4mm NC post-dilatation after 3 mm DES implantation. Primary endpoints were determined as target lesion revascularisation, cardiac mortality, and myocardial infarction associated with the target vessel. Our secondary endpoint was all-cause mortality. Results: No differences were observed between the groups in terms of the baseline variables. Stent length was the highest in Group II and the shortest in Group III. There were no significant differences between the groups regarding major adverse cardiovascular events (MACE). Conclusions: Our study suggests that in percutaneous coronary interventions for non-complex lesions, there is no significant difference in MACE outcomes when directly implanting a 4 mm diameter DES, a 4 mm diameter BMS, or a 3 mm diameter DES, followed by post-dilation with an appropriately sized NC balloon when the target vessel diameter is in the range of 4 to 4.4 mm.
- Open Access
- 28 November 2022
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 57 (1) , 25-30
Assessment of silent brain injury in patients undergoing elective percutaneous coronary intervention due to chronic total occlusion
Objective: Silent brain infarcts (SBI) are thromboembolic complications associated with cardiac surgery, diagnostic angiography, and percutaneous interventions. Serum neuron-specific enolase (NSE) is the proven biomarker for measuring neuronal damage. This study aimed to evaluate the incidence of SBI, defined as elevated NSE after coronary chronic total occlusion (CTO) intervention and elective coronary stenting. Design: The study population consisted of two patient groups: the CTO group included consecutive patients with coronary CTO intervention, and the control group consisted of patients who underwent elective coronary intervention. NSE blood levels were measured before and 12–18 h after the procedure. NSE blood levels of >20 ng/mL were considered SBI. Results: A total of 108 patients were included in the study. Of these, 55 (50.9%) had SBI after the procedure. The SBI rate was 59.7% in the CTO group and 39.1% in the control group. Patients with SBI were more likely to have diabetes mellitus, hyperlipidemia, higher HbA1c, higher total stent length, and longer procedural time. Multivariate logistic regression analysis showed that CTO procedure (odds ratio [OR]: 3.129; 95% confidence interval [CI]: 1.246–7.858; p < 0.015) and diabetes mellitus (OR: 2.93; 95% CI: 1.185–7.291; p < 0.020) are independent predictors of SBI. Conclusion: Our data suggest that SBI occurs more frequently after CTO intervention than after non-CTO intervention. Intervention complexity and patient clinical characteristics may explain the increased incidence.
- 28 November 2022
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 57 (1) , 25-30
Open AccessAssessment of silent brain injury in patients undergoing elective percutaneous coronary intervention due to chronic total occlusion
Objective: Silent brain infarcts (SBI) are thromboembolic complications associated with cardiac surgery, diagnostic angiography, and percutaneous interventions. Serum neuron-specific enolase (NSE) is the proven biomarker for measuring neuronal damage. This study aimed to evaluate the incidence of SBI, defined as elevated NSE after coronary chronic total occlusion (CTO) intervention and elective coronary stenting. Design: The study population consisted of two patient groups: the CTO group included consecutive patients with coronary CTO intervention, and the control group consisted of patients who underwent elective coronary intervention. NSE blood levels were measured before and 12–18 h after the procedure. NSE blood levels of >20 ng/mL were considered SBI. Results: A total of 108 patients were included in the study. Of these, 55 (50.9%) had SBI after the procedure. The SBI rate was 59.7% in the CTO group and 39.1% in the control group. Patients with SBI were more likely to have diabetes mellitus, hyperlipidemia, higher HbA1c, higher total stent length, and longer procedural time. Multivariate logistic regression analysis showed that CTO procedure (odds ratio [OR]: 3.129; 95% confidence interval [CI]: 1.246–7.858; p < 0.015) and diabetes mellitus (OR: 2.93; 95% CI: 1.185–7.291; p < 0.020) are independent predictors of SBI. Conclusion: Our data suggest that SBI occurs more frequently after CTO intervention than after non-CTO intervention. Intervention complexity and patient clinical characteristics may explain the increased incidence.
- Open Access
- 1 November 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (11) , 827-831
Evaluation of Long-Term Outcomes of Crossover or Focal Ostial Stenting of Left Anterior Descending Artery Ostial Stenosis
Medina,bifurcation,ostial,coronary,stenting
- 1 November 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (11) , 827-831
Open AccessEvaluation of Long-Term Outcomes of Crossover or Focal Ostial Stenting of Left Anterior Descending Artery Ostial Stenosis
Medina,bifurcation,ostial,coronary,stenting
- Open Access
- 1 April 2022
- Published by Wiley in Journal of Arrhythmia
- Vol. 38 (3) , 353-362
The predictive value of galectin‐3 levels on left atrial low voltage areas assessed by high‐density mapping in patients with paroxysmal atrial fibrillation
Aims: Galectin-3 is an inflammation biomarker that is associated with atrial fibrosis and plays a role in the development of atrial fibrillation (AF). Low voltage areas (LVAs) identified using an electroanatomical mapping system represent the presence of fibrotic tissue. The present study aimed to determine the relationship between coronary sinus (CS) serum sampling of galectin-3 levels and the presence and extent of LVA in patients with paroxysmal AF. Methods: A total of 115 consecutive paroxysmal AF patients underwent pulmonary vein isolation (PVI) included prospectively in the study. Voltage mapping was performed before PVI during sinus rhythm guided by multipolar high-density mapping catheter and LVAs were defined as regions where bipolar peak to peak voltage was <0.5 mV. Galectin-3 levels were measured via enzyme-linked immunosorbent assay. Results: CS serum sampling of galectin-3 levels was significantly higher in paroxysmal AF patients with LVA than those without LVA (16.5 +/- 3.7 ng/ml vs. 10.2 +/- 2.7 ng/ml, respectively, p < .001). CS serum sampling of galectin-3 levels was significantly higher in paroxysmal AF patients with moderate and severe LVA than in paroxysmal AF patients with mild LVA (17 +/- 3.5 ng/ml and 20.1 +/- 1.3 ng/ml vs. 13.3 +/- 2.3 ng/ml, respectively, p = .002). In the multivariate analysis female gender (odds ratio [OR] = 7.537, 95% confidence interval [CI]: 1.011-56.195; p = .049), left atrium volume (OR = 1.326, 95% CI: 1.052-1.67; p = .017), and CS serum sampling of galectin-3 levels (OR = 1.704, 95% CI: 1.169-2.483; p = .006) were significant and independent predictors for LVAs. Conclusion: In this study, we found that the CS serum sampling of galectin-3 levels increased with the extent of LVA and was an independent predictor for the presence of LVA.
- 1 April 2022
- Published by Wiley in Journal of Arrhythmia
- Vol. 38 (3) , 353-362
Open AccessThe predictive value of galectin‐3 levels on left atrial low voltage areas assessed by high‐density mapping in patients with paroxysmal atrial fibrillation
Aims: Galectin-3 is an inflammation biomarker that is associated with atrial fibrosis and plays a role in the development of atrial fibrillation (AF). Low voltage areas (LVAs) identified using an electroanatomical mapping system represent the presence of fibrotic tissue. The present study aimed to determine the relationship between coronary sinus (CS) serum sampling of galectin-3 levels and the presence and extent of LVA in patients with paroxysmal AF. Methods: A total of 115 consecutive paroxysmal AF patients underwent pulmonary vein isolation (PVI) included prospectively in the study. Voltage mapping was performed before PVI during sinus rhythm guided by multipolar high-density mapping catheter and LVAs were defined as regions where bipolar peak to peak voltage was <0.5 mV. Galectin-3 levels were measured via enzyme-linked immunosorbent assay. Results: CS serum sampling of galectin-3 levels was significantly higher in paroxysmal AF patients with LVA than those without LVA (16.5 +/- 3.7 ng/ml vs. 10.2 +/- 2.7 ng/ml, respectively, p < .001). CS serum sampling of galectin-3 levels was significantly higher in paroxysmal AF patients with moderate and severe LVA than in paroxysmal AF patients with mild LVA (17 +/- 3.5 ng/ml and 20.1 +/- 1.3 ng/ml vs. 13.3 +/- 2.3 ng/ml, respectively, p = .002). In the multivariate analysis female gender (odds ratio [OR] = 7.537, 95% confidence interval [CI]: 1.011-56.195; p = .049), left atrium volume (OR = 1.326, 95% CI: 1.052-1.67; p = .017), and CS serum sampling of galectin-3 levels (OR = 1.704, 95% CI: 1.169-2.483; p = .006) were significant and independent predictors for LVAs. Conclusion: In this study, we found that the CS serum sampling of galectin-3 levels increased with the extent of LVA and was an independent predictor for the presence of LVA.
- Open Access
- 31 March 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (4) , 249-257
Low-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review
Thrombotic coronary artery occlusions usually manifest as acute coronary syndrome with cardiogenic shock, acute pulmonary edema, cardiac arrest, fatal arrhythmias, or sudden cardiac death. Although it usually occurs based on atherosclerosis, ft can also occur without atherosclerosis. There is no predictor of coronary artery thrombosis clinically and no consensus regarding the optimal treatment. In the current literature, treatment options include emergency coronary artery bypass grafting, entrapment of thrombus in vessel wall with stent implantation, intracoronary thrombolysis, glycoprotein IIb/IIIa inhibitors, anticoagulation with heparin, and thrombus aspiration as reperfusion strategies. Here, we reviewed a new treatment strategy based on the literature, and a case series with successful results in hemodynamically stable patients with low-dose slow infusion tissue plasminogen activator (tPA) for thrombotic coronary artery occlusions that allow coronary flow was reported. Prospective randomized studies and common consensus are needed on low-dose, slow-infusion tissue plasminogen activator treatment regimen and optimal treatment management for thrombotic coronary artery occlusions.
- 31 March 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (4) , 249-257
Open AccessLow-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review
Thrombotic coronary artery occlusions usually manifest as acute coronary syndrome with cardiogenic shock, acute pulmonary edema, cardiac arrest, fatal arrhythmias, or sudden cardiac death. Although it usually occurs based on atherosclerosis, ft can also occur without atherosclerosis. There is no predictor of coronary artery thrombosis clinically and no consensus regarding the optimal treatment. In the current literature, treatment options include emergency coronary artery bypass grafting, entrapment of thrombus in vessel wall with stent implantation, intracoronary thrombolysis, glycoprotein IIb/IIIa inhibitors, anticoagulation with heparin, and thrombus aspiration as reperfusion strategies. Here, we reviewed a new treatment strategy based on the literature, and a case series with successful results in hemodynamically stable patients with low-dose slow infusion tissue plasminogen activator (tPA) for thrombotic coronary artery occlusions that allow coronary flow was reported. Prospective randomized studies and common consensus are needed on low-dose, slow-infusion tissue plasminogen activator treatment regimen and optimal treatment management for thrombotic coronary artery occlusions.
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 367-375
Thromboembolic complications in Takotsubo Syndrome during Covid-19 outbreak. A review with case report
New coronavirus (COVID-19) outbreak, which started in Wuhan, China and spread rapidly all over the world, has become the most important cause of the emotional distress for susceptible people. Because the people also remained in fear and anxiety during the period when the elderly population in the whole country was desperate due to the COVID-19 outbreak and was asked to stay at home in fear of death. In addition, the fact that the patients were hospitalized together with COVID-19 patients caused his psychological distress to be experienced even more. Takotsubo Syndrome (TTS) is known as a distress-induced transient left ventricular dysfunction. In our patient with TTS, it was found that a new apical thrombus, which was not seen in the left ventricle, was seen in previous echo and computerized tomographic investigation, and that it was a source of thromboemboli, by stress triggering neurocardiac reactions. While under the medical treatment of viral pneumonia, under the Coronavirus transmission measures, thrombus in the LV was removed by being taken to the emergency open heart surgery. Our case is the first patient in the literature where a new thrombus developed in the LV and splenic infarction in TTS triggered by the pandemic. In this article; We have presented the experience of TTS triggered by pandemic, etiopathogenesis of left ventricular thrombus, open heart surgery indications when COVID-19 is suspected, coronavirus transmission measures in the surgical approach, the postoperative treatment and literature is reviewed.
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 367-375
Thromboembolic complications in Takotsubo Syndrome during Covid-19 outbreak. A review with case report
New coronavirus (COVID-19) outbreak, which started in Wuhan, China and spread rapidly all over the world, has become the most important cause of the emotional distress for susceptible people. Because the people also remained in fear and anxiety during the period when the elderly population in the whole country was desperate due to the COVID-19 outbreak and was asked to stay at home in fear of death. In addition, the fact that the patients were hospitalized together with COVID-19 patients caused his psychological distress to be experienced even more. Takotsubo Syndrome (TTS) is known as a distress-induced transient left ventricular dysfunction. In our patient with TTS, it was found that a new apical thrombus, which was not seen in the left ventricle, was seen in previous echo and computerized tomographic investigation, and that it was a source of thromboemboli, by stress triggering neurocardiac reactions. While under the medical treatment of viral pneumonia, under the Coronavirus transmission measures, thrombus in the LV was removed by being taken to the emergency open heart surgery. Our case is the first patient in the literature where a new thrombus developed in the LV and splenic infarction in TTS triggered by the pandemic. In this article; We have presented the experience of TTS triggered by pandemic, etiopathogenesis of left ventricular thrombus, open heart surgery indications when COVID-19 is suspected, coronavirus transmission measures in the surgical approach, the postoperative treatment and literature is reviewed.
- 1 March 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (3) , 719-723
Evaluation of Mesenteric Artery Disease in Patients with Severe Aortic Valve Stenosis
The aim of this study is to evaluate the mesenteric artery stenosis (MAS) in routinely performed CT angiography (CTA) of patients with severe aortic stenosis (AS) planned for transcatheter aortic valve implantation (TAVI) before the procedure. Patients with AS (AS group) who routinely underwent CTA before the TAVI procedure due to severe AS and patients who had CTA for other indications (control group) were retrospectively and sequentially scanned. The demographic characteristics of the patients in both groups were similar. Calcification and stenosis in the mesenteric arteries were recorded according to the localization of celiac truncus, superior mesenteric artery (SMA) and inferior mesenteric artery (IMA). Class 0-3 classification was used for calcification score. Stenoses with a stenosis degree ≥50% were considered as significant. A total of 184 patients, 73 patients with severe AS and 111 control groups, were included in the study. SMA and IMA calcification scores of patients with AS were significantly higher than the control group (p=0.035 for SMA and p=0.020 for IMA). In addition, the rate of patients with significant MAS in at least 1 artery (45.2% vs 22.5%, p=0.001) and the rate of patients with significant stenosis in multiple arteries were also significantly higher in the AS group (8.2% vs 1.8%, p=0.037). According to the study results, patients with AS are at a higher risk for MAS. Chronic mesenteric ischemia should be kept in mind in patients with AS who have symptoms such as non-specific abdominal pain and weight loss.
- 1 March 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (3) , 719-723
Evaluation of Mesenteric Artery Disease in Patients with Severe Aortic Valve Stenosis
The aim of this study is to evaluate the mesenteric artery stenosis (MAS) in routinely performed CT angiography (CTA) of patients with severe aortic stenosis (AS) planned for transcatheter aortic valve implantation (TAVI) before the procedure. Patients with AS (AS group) who routinely underwent CTA before the TAVI procedure due to severe AS and patients who had CTA for other indications (control group) were retrospectively and sequentially scanned. The demographic characteristics of the patients in both groups were similar. Calcification and stenosis in the mesenteric arteries were recorded according to the localization of celiac truncus, superior mesenteric artery (SMA) and inferior mesenteric artery (IMA). Class 0-3 classification was used for calcification score. Stenoses with a stenosis degree ≥50% were considered as significant. A total of 184 patients, 73 patients with severe AS and 111 control groups, were included in the study. SMA and IMA calcification scores of patients with AS were significantly higher than the control group (p=0.035 for SMA and p=0.020 for IMA). In addition, the rate of patients with significant MAS in at least 1 artery (45.2% vs 22.5%, p=0.001) and the rate of patients with significant stenosis in multiple arteries were also significantly higher in the AS group (8.2% vs 1.8%, p=0.037). According to the study results, patients with AS are at a higher risk for MAS. Chronic mesenteric ischemia should be kept in mind in patients with AS who have symptoms such as non-specific abdominal pain and weight loss.
- 1 January 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (1) , 20-27
Galectin-3 levels and the prediction of atrial high-rate episodes in patients with cardiac resynchronization therapy
Galectin-3 is an inflammation biomarker associated with atrial remodeling which plays a role in the development of atrial fibrillation (AF). Atrial high-rate episode (AHRE) is related to development of clinically documented AF and stroke. The present study aimed to determine the relationship between the presence of AHRE and the coronary sinus (CS) serum sampling of galectin-3 levels in the long-term follow-up of cardiac resynchronization therapy (CRT) patients. A total of 108 consecutive CRT patients were included prospectively in the study. AHREs were defined as atrial tachyarrhythmia episodes lasting at least 6 min with atrial rate >190 beats/min detected by cardiac implantable electronic device. CS blood samples were drawn from the CS guiding catheter to perform galectin-3 measurements. Galectin-3 levels were measured via ELISA. During a mean follow-up 12.6±4.9 months, AHRE was observed in 31 (28.7%) patients and not observed in 77 (72.3%) patients. CS galectin-3 levels were significantly higher in patients with AHRE than those without AHRE (18.09±2.62 vs 13.17±3.17, respectively, p<0.001). Moreover, CS galectin-3 levels showed significant positive correlation with percent of time spent in total AHRE (r=0.436, p<0.001). Multivariate logistic regression analysis demonstrated that left atrium (LA) volume and CS galectin-3 levels were significant and independent predictors for AHRE (OR=1.127, 95% CI: 1.045 to 1.216; p=0.002, OR=1.799, 95% CI: 1.388 to 2.330; p<0.001, respectively). In this study, we determined that high CS galectin-3 levels were a predictor for the development of AHRE in CRT patients.
- 1 January 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (1) , 20-27
Galectin-3 levels and the prediction of atrial high-rate episodes in patients with cardiac resynchronization therapy
Galectin-3 is an inflammation biomarker associated with atrial remodeling which plays a role in the development of atrial fibrillation (AF). Atrial high-rate episode (AHRE) is related to development of clinically documented AF and stroke. The present study aimed to determine the relationship between the presence of AHRE and the coronary sinus (CS) serum sampling of galectin-3 levels in the long-term follow-up of cardiac resynchronization therapy (CRT) patients. A total of 108 consecutive CRT patients were included prospectively in the study. AHREs were defined as atrial tachyarrhythmia episodes lasting at least 6 min with atrial rate >190 beats/min detected by cardiac implantable electronic device. CS blood samples were drawn from the CS guiding catheter to perform galectin-3 measurements. Galectin-3 levels were measured via ELISA. During a mean follow-up 12.6±4.9 months, AHRE was observed in 31 (28.7%) patients and not observed in 77 (72.3%) patients. CS galectin-3 levels were significantly higher in patients with AHRE than those without AHRE (18.09±2.62 vs 13.17±3.17, respectively, p<0.001). Moreover, CS galectin-3 levels showed significant positive correlation with percent of time spent in total AHRE (r=0.436, p<0.001). Multivariate logistic regression analysis demonstrated that left atrium (LA) volume and CS galectin-3 levels were significant and independent predictors for AHRE (OR=1.127, 95% CI: 1.045 to 1.216; p=0.002, OR=1.799, 95% CI: 1.388 to 2.330; p<0.001, respectively). In this study, we determined that high CS galectin-3 levels were a predictor for the development of AHRE in CRT patients.